Too little aspirin for secondary prevention after acute myocardial infarction in patients at high risk for cardiovascular events: Results from the MITRA study

American Heart Journal

Volumn 148, Issue 2, 2004, Pages 306-311

  Frilling, Birgit ^a   Schiele, Rudolf ^a   Gitt, Anselm Kai ^a   Zahn, Ralf ^a   Schneider, Steffen ^a   Glunz, Hans Georg ^b   Gieseler, Ulf ^c   Jagodzinski, Edwin ^d   Senges, Jochen ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b Westpfalz Klinikum GmbH   (Germany)

^c Diakonissenkrankenhaus Speyer   (Germany)

^d Marienkrankenhaus Ludwigshafen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONTRAINDICATION; FEMALE; FOLLOW UP; GERMANY; HIGH RISK POPULATION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; MULTIVARIATE ANALYSIS; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; TREATMENT WITHDRAWAL;

AGED; ASPIRIN; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RECURRENCE; REGISTRIES; RISK FACTORS;

EID: 4143104655     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.01.027     Document Type: Article

References (20)

1. Califf R.M., Van de Werf F., Sadowski Z., et al. One year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-1) trial GUSTO-1 Investigators. Circulation. 94:1996;1233-1238
2. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction ISIS-1. Lancet. 2:1986;57-66
3. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of anti-platelet therapy. I Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 308:1994;81-106
4. Pfeffer M.A., Braunwald E., Moyé L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction results from the Survival and Ventricular Enlargement (SAVE) study. N Engl J Med. 327:1992;669-677
5. The Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357
6. McLaughlin T.J., Soumerai S.B., Willison D.J., et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction. Arch Intern Med. 156:1996;799-805
7. Kizer J.R., Cannon C.P., McCabe C.H., et al. Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice the MILIS-TIMI experience. Am Heart J. 137:1999;79-92
8. Rogers W.J., Bowlby I.J., Chandra N.C., et al. Treatment of myocardial infarction in the United States (1990 to 1993) observations from the National Registry of Myocardial Infarction. Circulation. 90:1994;2103-2114
9. Frilling B., Schiele R., Gitt A.K., et al. Characterization and clinical course of patients not receiving aspirin for acute myocardial infarction results from the MITRA and MIR studies. Am Heart J. 141:2001;200-205
10. Schuster S., Koch A., Burczyk U., et al. Therapy of acute myocardial infarction, impact of clinical trials on clinical practice the MITRA pilot phase. Z Kardiol. 86:1997;273-283
11. Peto R. Aspirin after myocardial infarction. Lancet. I:1980;1172-1173
12. Hochmann J.S., Sleeper L.A., Webb J.G., et al. Should we emergently revascularize occluded coronaries for cardiogenic shock? N Engl J Med. 341:1999;625-634
13. ISIS-3 Collaborative Group. A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41299 cases of suspected acute myocardial infarction. Lancet. 339:1992;753-770
14. Ziljstra F., de Boer M.J., Hoorntje J.C.A., et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med. 328:1993;680-684
15. Roderick P.J., Wilkes H.C., Meade T.W. The gastrointestinal toxicity of aspirin an overview of randomised trials. Br J Clin Pharmacol. 35:1993;219-226
16. Steering committee of the Physicians' Health Study Research Group. Preliminary report findings from the aspirin component of the ongoing physicians' health study. N Engl J Med. 318:1988;262-264
17. CAPRIE steering committee. A randomised, blinded trial of clopidogrel vs. aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 348:1996;1329-1339
18. Gottwik M., Zahn R., Schiele R., et al. Differences in treatment and outcome of patients with acute myocardial infarction admitted to hospitals with compared to without departments of cardiology. Eur Heart J. 22:2001;1794-1802
19. Ayanian J.Z., Hauptmann P.J., Guadagnoli E., et al. Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med. 331:1994;1136-1142
20. Wagner S., Schneider S., Schiele R., et al. Acute myocardial infarction in Germany between 1996 and 1998 therapy and intrahospital course. Results of the myocardial infarction registry. Z Kardiol. 88:1999;857-865